GERN
Price
$1.15
Change
-$0.09 (-7.26%)
Updated
Nov 13 closing price
Capitalization
734.11M
118 days until earnings call
Intraday BUY SELL Signals
SER
Price
$3.92
Change
-$0.10 (-2.49%)
Updated
Nov 13 closing price
Capitalization
41.31M
Intraday BUY SELL Signals
Interact to see
Advertisement

GERN vs SER

Header iconGERN vs SER Comparison
Open Charts GERN vs SERBanner chart's image
Geron
Price$1.15
Change-$0.09 (-7.26%)
Volume$7.53M
Capitalization734.11M
Serina Therapeutics
Price$3.92
Change-$0.10 (-2.49%)
Volume$16.63K
Capitalization41.31M
GERN vs SER Comparison Chart in %
GERN
Daily Signal:
Gain/Loss:
SER
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GERN vs. SER commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Hold and SER is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (GERN: $1.24 vs. SER: $4.02)
Brand notoriety: GERN and SER are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GERN: 83% vs. SER: 48%
Market capitalization -- GERN: $734.11M vs. SER: $41.31M
GERN [@Biotechnology] is valued at $734.11M. SER’s [@Biotechnology] market capitalization is $41.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GERN’s FA Score shows that 0 FA rating(s) are green whileSER’s FA Score has 0 green FA rating(s).

  • GERN’s FA Score: 0 green, 5 red.
  • SER’s FA Score: 0 green, 5 red.
According to our system of comparison, GERN is a better buy in the long-term than SER.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GERN’s TA Score shows that 6 TA indicator(s) are bullish while SER’s TA Score has 4 bullish TA indicator(s).

  • GERN’s TA Score: 6 bullish, 3 bearish.
  • SER’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, GERN is a better buy in the short-term than SER.

Price Growth

GERN (@Biotechnology) experienced а +13.76% price change this week, while SER (@Biotechnology) price change was -7.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

GERN is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GERN($734M) has a higher market cap than SER($41.3M). SER YTD gains are higher at: -19.760 vs. GERN (-64.972). SER has higher annual earnings (EBITDA): -12.47M vs. GERN (-58.41M). GERN has more cash in the bank: 388M vs. SER (6.04M). SER has less debt than GERN: SER (185K) vs GERN (122M). GERN has higher revenues than SER: GERN (164M) vs SER (0).
GERNSERGERN / SER
Capitalization734M41.3M1,777%
EBITDA-58.41M-12.47M469%
Gain YTD-64.972-19.760329%
P/E RatioN/A1.63-
Revenue164M0-
Total Cash388M6.04M6,423%
Total Debt122M185K65,946%
FUNDAMENTALS RATINGS
GERN vs SER: Fundamental Ratings
GERN
SER
OUTLOOK RATING
1..100
6217
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
6487
P/E GROWTH RATING
1..100
66100
SEASONALITY SCORE
1..100
28n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SER's Valuation (74) in the null industry is in the same range as GERN (95) in the Biotechnology industry. This means that SER’s stock grew similarly to GERN’s over the last 12 months.

SER's Profit vs Risk Rating (100) in the null industry is in the same range as GERN (100) in the Biotechnology industry. This means that SER’s stock grew similarly to GERN’s over the last 12 months.

GERN's SMR Rating (96) in the Biotechnology industry is in the same range as SER (100) in the null industry. This means that GERN’s stock grew similarly to SER’s over the last 12 months.

GERN's Price Growth Rating (64) in the Biotechnology industry is in the same range as SER (87) in the null industry. This means that GERN’s stock grew similarly to SER’s over the last 12 months.

GERN's P/E Growth Rating (66) in the Biotechnology industry is somewhat better than the same rating for SER (100) in the null industry. This means that GERN’s stock grew somewhat faster than SER’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GERNSER
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
77%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
GERN
Daily Signal:
Gain/Loss:
SER
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LBRDA49.030.92
+1.91%
Liberty Broadband Corp
JPM320.414.79
+1.52%
JPMorgan Chase & Co
LPBB10.48N/A
N/A
Launch Two Acquisition Corp
VRE14.95-0.39
-2.54%
Veris Residential
TSE1.14-0.09
-7.32%
Trinseo PLC

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-0.80%
SER - GERN
66%
Loosely correlated
-1.47%
LIANY - GERN
53%
Loosely correlated
+6.48%
VCYT - GERN
44%
Loosely correlated
-0.84%
SYRE - GERN
40%
Loosely correlated
+0.34%
BMRN - GERN
38%
Loosely correlated
+0.71%
More

SER and

Correlation & Price change

A.I.dvisor indicates that over the last year, SER has been closely correlated with LIANY. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if SER jumps, then LIANY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SER
1D Price
Change %
SER100%
-1.47%
LIANY - SER
69%
Closely correlated
+6.48%
GERN - SER
65%
Loosely correlated
-0.80%
XTLB - SER
59%
Loosely correlated
-2.03%
ELVN - SER
37%
Loosely correlated
+3.36%
TOVX - SER
34%
Loosely correlated
+8.05%
More